The status of the research on muon colliders is discussed and plans are outlined for future theoretical and experimental studies. Besides work on the parameters of a 3-4 and 0.5 TeV center-of-mass (COM) energy collider, many studies are now concentrating on a machine near 0.1 TeV (COM) that could be a factory for the s-channel production of Higgs particles. We discuss the research on the various components in such muon colliders, starting from the proton accelerator needed to generate pions from 1098-4402͞99͞2(8)͞081001(73)$15.00 © 1999 The American Physical Society 081001-1 PRST-AB 2 CHARLES M. ANKENBRANDT et al. 081001 (1999) a heavy-Z target and proceeding through the phase rotation and decay (p ! m n m ) channel, muon cooling, acceleration, storage in a collider ring, and the collider detector. We also present theoretical and experimental R&D plans for the next several years that should lead to a better understanding of the design and feasibility issues for all of the components. This report is an update of the progress on the research and development since the feasibility study of muon colliders presented at the Snowmass '96

Objective: To reinvestigate ultra-high dose rate radiation (UHDRR) radiobiology and consider potential implications for hadrontherapy. Methods: A literature search of cellular UHDRR exposures was performed. Standard oxygen diffusion equations were used to estimate the time taken to replace UHDRRrelated oxygen depletion. Dose rates from conventional and novel methods of hadrontherapy accelerators were considered, including spot scanning beam delivery, which intensifies dose rate. Results: The literature findings were that, for X-ray and electron dose rates of around 10 9 Gy s -1 , 5-10 Gy depletes cellular oxygen, significantly changing the radiosensitivity of cells already in low oxygen tension (around 3 mmHg or 0.4 kPa). The time taken to reverse the oxygen depletion of such cells is estimated to be over 20-30 s at distances of over 100 mm from a tumour blood vessel. In this time window, tumours have a higher hypoxic fraction (capable of reducing tumour control), so the next application of radiation within the same fraction should be at a time that exceeds these estimates in the case of scanned beams or with ultra-fast laser-generated particles. Conclusion: This study has potential implications for particle therapy, including lasergenerated particles, where dose rate is greatly increased. Conventional accelerators probably do not achieve the critical UHDRR conditions. However, specific UHDRR oxygen depletion experiments using proton and ion beams are indicated.

We describe the status of our effort to realize a first neutrino factory and the progress made in understanding the problems associated with the collection and cooling of muons towards that end. We summarize the physics that can be done with neutrino factories as well as with intense cold beams of muons. The physics potential of muon colliders is reviewed, both as Higgs factories and compact highenergy lepton colliders. The status and time scale of our research and development effort is reviewed as well as the latest designs in cooling channels including the promise of ring coolers in achieving longitudinal and transverse cooling simultaneously. We detail the efforts being made to mount an international cooling experiment to demonstrate the ionization cooling of muons.

No abstract

The conceptual design for a nonscaling fixed field alternating gradient accelerator suitable for charged particle therapy (the use of protons and other light ions to treat some forms of cancer) is described.